Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir (Q43485506)

23 November 2017

Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir (English)

1 reference

23 November 2017

1 reference

Mike Bray

1

1 reference

23 November 2017

Mark Martinez

2

1 reference

23 November 2017

Deborah Kefauver

3

1 reference

23 November 2017

Michael West

4

1 reference

23 November 2017

Chad Roy

5

1 reference

23 November 2017

1 June 2002

1 reference

23 November 2017

1 reference

23 November 2017

54

1 reference

23 November 2017

3

1 reference

23 November 2017

129-142

1 reference

1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Drug delivery via the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Pharmacokinetics of ribavirin aerosol in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Measurement of the respiratory volumes of laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Bioterrorism as a public health threat

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Antiviral therapy with small particle aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Prevention and treatment of respiratory syncytial virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Smallpox: An attack scenario

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900220-0

7 January 2021

10.1016/S0166-3542(01)00220-0

Identifiers

DOI

1 reference

23 November 2017

1 reference